Phase III study of Conmana shows benefits for NSCLC
A randomised, double-blind, Phase III non-inferiority trial of 400 patients with advanced Non-Small-Cell Lung Cancer showed that Conmana (icotinib), from Zhejang Beta Pharma, was non-inferior to gefitinib in terms of progression-free survival (median progression-free survival 4�6 months vs 3�4 months). The most common adverse events were rash (41% in the icotinib group vs 49% in the gefitinib group) and diarrhoea (22% vs 29%).
Conmana was approved in China in June 2011. Results were published in The Lancet: "Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind Phase 3 non-inferiority trial." Yuankai Shi et al. The Lancet Oncology, 13 August 2013 doi:10.1016/S1470-2045(13)70355-3
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins